Thursday, March 3, 2022

DSGMC to send a 20-members delegation to help the stranded Indian students in Ukraine

New Delhi, March 3,  Harmeet Singh Kalka, President, and Jagdip Singh Kahlon, General Secretary, Delhi Sikh Gurdwara Management Committee (DSGMC) has informed the media that Delhi Sikh Committee will send a 20-member delegation to help the stranded people in Ukraine. The delegation will comprise of senior members, staff, and volunteers. 


The delegation will be divided into two parts- one part will visit the border of Poland and the other will visit Slovakia to help the stranded people there.  Special camps will be organized there to distribute langar, medical assistance and extend all possible assistance to the stranded people on humanitarian grounds. They said after the war, the situation gets worsened and people need much more assistance. DSGMC deems its duty to send the delegation to serve the people in distress. 

Kalka and Kahlon further said that DSGMC stands at the forefront to provide its services to needy people at the time of natural calamities. In the past, DSGMC has done commendable service whenever the country needed for example at the time of natural calamities in Uttrakhand, Gujarat, Kashmir, Uttar Pradesh, Punjab and in Nepal and other places in abroad. The motto of the DSGMC is to serve humanity following the teachings of our Guru Sahibs

WHO updates its treatment guidelines to include molnupiravir

This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant



Geneva, 3 March 2022 | WHO has updated its living guidelines on COVID-19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine.

This is the first oral antiviral drug to be included in the treatment guidelines for COVID-19. As this is a new medicine, there is little safety data. WHO recommends active monitoring for drug safety, along with other strategies to mitigate potential harms.

Because of these concerns and data gaps, molnupiravir should be provided only to non-severe COVID-19 patients with the highest risk of hospitalization. These are typically people who have not received a COVID-19 vaccination, older people, people with immunodeficiencies and people living with chronic diseases.

Children, and pregnant and breastfeeding women should not be given the drug. People who take molnupiravir should have a contraceptive plan, and health systems should ensure access to pregnancy testing and contraceptives at the point of care.

Under the care of a health care provider, molnupiravir, an oral tablet, is given as four tablets (total 800 mg) twice daily for five days; within 5 days of symptom onset. Used as early as possible after infection, it can help prevent hospitalization.

Today’s recommendation is based on new data from six randomized controlled trials involving 4,796 patients. This is the largest dataset on this drug so far.

Along with a recommendation on molnupiravir, this ninth update of WHO’s living guideline on therapeutics includes an update on casirivimab-imdevimab, a monoclonal antibody cocktail. Based on evidence that this combination of drugs is ineffective against the Omicron variant of concern, WHO now recommends that it is only given when the infection is caused by another variant.

Molnupiravir is not widely available but steps have been taken towards increasing access, including the signing of a voluntary licensing agreement. The Access to COVID-19 Tools Accelerator (ACT-A) is making a limited supply available to countries with access constraints.

WHO has also invited manufacturers to submit their products for prequalification, with a number of manufacturers of molnupiravir going through assessment now. WHO evaluates the quality, safety and efficacy of medical products for United Nations and other large suppliers to low- and middle-income countries. More WHO quality-assured manufacturers mean that countries have a greater choice of products and more competitive prices.  

Thanks: WHO

WHO and MPP welcome NIH’s offer of COVID-19 health technologies to C-TAP

Geneva, 3 March 2022 – The World Health Organization (WHO) and the Medicines Patent Pool (MPP) jointly welcome the announcement that the United States National Institutes of Health (NIH) will offer several technologies to the COVID-19 Technology Access Pool (C-TAP) for potential licensing through MPP. The announcement was made today at the U.S. COVID-19 Dialogue with Ministers of Health meeting in the presence of WHO Director-General, Dr Tedros Adhanom Ghebreyesus, and NIAID Director and Chief Medical Advisor to the President of United States, Anthony Fauci.


“I thank NIH for its offer of innovative therapeutics, vaccines and diagnostic methods for COVID-19,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Voluntary sharing of technologies through non-exclusive agreements will not only help us put the pandemic behind us; it will also empower low- and middle-income countries to produce their own medical products and achieve equitable access.”

“NIH were the first to share their patents with MPP for an HIV product back in 2010 when we were created,” said Charles Gore, MPP Executive Director. “We will be honoured to sign public health-driven transparent non-exclusive licence agreements with NIH under the auspices of C-TAP when the negotiations have concluded, with the goal to provide access of these innovative technologies to people in need around the world and help put an end to the pandemic.”

Launched in 2020 by the WHO Director-General and the President of Costa Rica, and supported by 43 Member States, C-TAP aims to facilitate timely, equitable and affordable access to COVID-19 health products by boosting their production and supply through open, non-exclusive licensing agreements. MPP provides the licensing expertise to this initiative and holds the licences.

Thanks: WHO

Wednesday, March 2, 2022

COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide

A wake-up call to all countries to step up mental health services and support


2 March 2022 - In the first year of the COVID-19 pandemic, global prevalence of anxiety and depression increased by a massive 25%, according to a scientific brief released by the World Health Organization (WHO) today. The brief also highlights who has been most affected and summarizes the effect of the pandemic on the availability of mental health services and how this has changed during the pandemic.

Concerns about potential increases in mental health conditions had already prompted 90% of countries surveyed to include mental health and psychosocial support in their COVID-19 response plans, but major gaps and concerns remain.

“The information we have now about the impact of COVID-19 on the world’s mental health is just the tip of the iceberg,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This is a wake-up call to all countries to pay more attention to mental health and do a better job of supporting their populations’ mental health.”

Multiple stress factors

One major explanation for the increase is the unprecedented stress caused by the social isolation resulting from the pandemic. Linked to this were constraints on people’s ability to work, seek support from loved ones and engage in their communities.

Loneliness, fear of infection, suffering and death for oneself and for loved ones, grief after bereavement and financial worries have also all been cited as stressors leading to anxiety and depression. Among health workers, exhaustion has been a major trigger for suicidal thinking.

Young people and women worst hit

The brief, which is informed by a comprehensive review of existing evidence about the impact of COVID-19 on mental health and mental health services, and includes estimates from the latest Global Burden of Disease study, shows that the pandemic has affected the mental health of young people and that they are disproportionally at risk of suicidal and self-harming behaviours. It also indicates that women have been more severely impacted than men and that people with pre-existing physical health conditions, such as asthma, cancer and heart disease, were more likely to develop symptoms of mental disorders.

Data suggests that people with pre-existing mental disorders do not appear to be disproportionately vulnerable to COVID-19 infection. Yet, when these people do become infected, they are more likely to suffer hospitalization, severe illness and death compared with people without mental disorders. People with more severe mental disorders, such as psychoses, and young people with mental disorders, are particularly at risk.

Gaps in care

This increase in the prevalence of mental health problems has coincided with severe disruptions to mental health services, leaving huge gaps in care for those who need it most. For much of the pandemic, services for mental, neurological and substance use conditions were the most disrupted among all essential health services reported by WHO Member States. Many countries also reported major disruptions in life-saving services for mental health, including for suicide prevention.

By the end of 2021 the situation had somewhat improved but today too many people remain unable to get the care and support they need for both pre-existing and newly developed mental health conditions.

Unable to access face-to-face care, many people have sought support online, signaling an urgent need to make reliable and effective digital tools available and easily accessible. However, developing and deploying digital interventions remains a major challenge in resource-limited countries and settings.

WHO and country action

Since the early days of the pandemic, WHO and partners have worked to develop and disseminate resources in multiple languages and formats to help different groups cope with and respond to the mental health impacts of COVID-19. For example, WHO produced a story book for 6-11-year-olds, My Hero is You, now available in 142 languages and 61 multimedia adaptations, as well as a toolkit for supporting older adults available in 16 languages.

At the same time, the Organization has worked with partners, including other United Nations agencies, international nongovernmental organizations and the Red Cross and Red Crescent Societies, to lead an interagency mental health and psychosocial response to COVID-19. Throughout the pandemic, WHO  has also worked to promote the integration of mental health and psychosocial support across and within all aspects of the global response. 

WHO Member States have recognized the impact of COVID-19 on mental health and are taking action. WHO’s most recent pulse survey on continuity of essential health services indicated that 90% of countries are working to provide mental health and psychosocial support to COVID-19 patients and responders alike. Moreover, at last year’s World Health Assembly, countries emphasized the need to develop and strengthen mental health and psychosocial support services as part of strengthening preparedness, response and resilience to COVID-19 and future public health emergencies. They adopted the updated Comprehensive Mental Health Action Plan 2013-2030, which includes an indicator on preparedness for mental health and psychosocial support in public health emergencies.

Step up investment

However, this commitment to mental health needs to be accompanied by a global step up in investment. Unfortunately, the situation underscores a chronic global shortage of mental health resources that continues today. WHO’s most recent Mental Health Atlas showed that in 2020, governments worldwide spent on average just over 2% of their health budgets on mental health and many low-income countries reported having fewer than 1 mental health worker per 100 000 people.

Dévora Kestel, Director of the Department of Mental Health and Substance Use at WHO, sums up the situation: ”While the pandemic has generated interest in and concern for mental health, it has also revealed historical under-investment in mental health services. Countries must act urgently to ensure that mental health support is available to all.”

with thanks : WHO

Thursday, February 24, 2022

Bloggerpride Platform for YouTubers, Vloggers, Bloggers & Instagramers

We will soon add a Directory Section on our BloggerPride Blog, where we will allow YouTubers, Bloggers, Vloggers, as well Instagramers to add all of their Links under the single heading. Feel free to Email us your details or add them in the comments below. You can also DM us @vohrabs on Twitter.


#Bloggers #Vloggers #YouTubers #Instagramers #Bloggerpride

www.bloggerpride.blogspot.com

youtube.com/c/BLOGGERPRIDE

Ice Cream in clouds #shorts #icecream #yummy धुआं धुआं